In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Wins Specialty CV Deal

Executive Summary

Bayer will pay $50 million up front and up to $335 million in development and commercialization milestones for ex-US rights to Nuvelo's clot-buster alfimeprase, which complements the German group's specialist cardiovascular portfolio.

You may also be interested in...



Bayer/Regeneron: Typically Rich, Extra Regional

Regeneron Pharmaceuticals' October 18th deal with Bayer is the perfect case-study for observers of today's biopharma sector: high-value, ex-US only, specialist, and with a nice split-indication twist in its tail.

Auctions: Getting the Best Value for Your Asset

Given the competition for increasingly rare pipeline-fillers, most of today's licensing and M&A deals are auctions--a term used loosely to describe any situation where there's more than one bidder for an asset. But auctions come in various flavors; knowing which one to use requires a deep understanding of your asset, and its value to others.

Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma

No one at the PSA conference disagreed with the meeting's basic premise: that externalization in nearly every aspect of the pharmaceutical business is increasing, both voluntarily and involuntarily as small companies gain increasing development and commercial rights to products they out-license. But there was considerable disagreement on just what needs to be externalized. The philosophical split was evident between companies and within them. The strategic imperative was obvious: drug companies need to assess what they're good at and what they're not. But few companies are honest about that, particularly given the amounts of infrastructure that might need to be cut.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1129788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel